bremelanotide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-12. Numbers and descriptions here follow the published literature rather than marketing material.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular weight | Approximately 1025 Da | Calculated from the peptide sequence |
| Appearance | White to off-white powder | Common for lyophilized peptide preparations |
| Solubility | Soluble in water | Also soluble in polar organic solvents |
| Storage temperature | -20 °C or below | Used for long-term retention |
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
=== Hydrides, carbides and nitrides === Uranium metal heated to 250 to 300 °C (482 to 572 °F) reacts with hydrogen to form uranium hydride. Even higher temperatures will reversibly remove the hydrogen. This property makes uranium hydrides convenient starting materials to create reactive uranium powder along with various uranium carbide, nitride, and halide compounds. Two crystal modifications of uranium hydride exist: an α form that is obtained at low temperatures and a β form that is created when the formation temperature is above 250 °C. Uranium carbides and uranium nitrides are both relatively inert semimetallic compounds that are minimally soluble in acids, react with water, and can ignite in air to form U3O8. Carbides of uranium include uranium monocarbide (UC), uranium dicarbide (UC2), and diuranium tricarbide (U2C3). Both UC and UC2 are formed by adding carbon to molten uranium or by exposing the metal to carbon monoxide at high temperatures. Stable below 1800 °C, U2C3 is prepared by subjecting a heated mixture of UC and UC2 to mechanical stress. Uranium nitrides obtained by direct exposure of the metal to nitrogen include uranium mononitride (UN), uranium dinitride (UN2), and diuranium trinitride (U2N3).
=== Intracrines and regenerative Medicine === The discovery of intracrine loops in stem cell regulation has profound implications for regenerative medicine. Because intracrines can establish long-lasting differentiation programs, they offer potential therapeutic targets for tissue regeneration and repair. For example, in cardiac repair, HMGB1 has been shown to enhance the proliferation and differentiation of cardiac stem cells following myocardial infarction, suggesting that modulating intracrine pathways could improve heart regeneration. The ability of certain intracrines to reprogram cells into pluripotent-like states also opens new avenues for regenerative therapies. Oct3/4, Sox2, and Nanog, all of which are involved in maintaining stem cell pluripotency, can potentially be introduced into cells to drive reprogramming without the need for genetic modification. This approach could provide safer and more controlled methods for generating patient-specific stem cells.
=== Leadership under Brian L. Halla === National Semiconductor announced the appointment of Brian L. Halla as its chairman, president and CEO on May 3, 1996. Halla was then the head of LSI logic products division. Prior to LSI, he had been with Intel for 14 years. Halla reinforced Amelio's emphasis on the expertise of National Semiconductor in analog technology. He also was, on occasions, an evangelist for analog technology. However, he found that National Semiconductor under Amelio had too few product offerings. Halla embarked on a diversification into personal computer and graphics business. He advocated PC-on-a-chip (aka system-on-a-chip) as a business direction for National Semiconductor. During his tenure at LSI, LSI had successfully applied similar concepts. However, LSI had steered clear of getting involved with PC technologies that would make it a competitor with Intel. Halla held the vision that information appliances (IAs) would succeed the personal computer as a trend. He predicted that IAs would overtake sales of PCs by the year 2000. To achieve the goal, National Semiconductor started acquiring companies that would provide the needed technological complements. Among the acquisitions were Cirrus Logic Inc's PicoPower business, for its specialised expertise in small form factor devices; Mediamatics Inc, which makes multimedia connectivity products; Future Integrated Systems Inc, a PC graphics company; Gulbransen Inc, a digital audio technology maker; ComCore Semiconductor Inc, a maker of digital signal processing for LANs; Cyrix, the maker of Intel x86 clones.
Sources: en.wikipedia.org
7-Eleven opened its first store in China in Shenzhen, Guangdong in 1992 and later expanded to Beijing in 2004, Tianjin and Shanghai in 2009, Chengdu in 2011, Qingdao in 2012, Chongqing in 2013, Hangzhou and Ningbo in 2017, Nanjing in 2018, and Wuhan, Xi'an, and Fuzhou in 2019. In China's 7-Eleven stores where Slurpees are offered, the Chinese name 思乐冰 (sīlèbīng) is used. They also offer a wide array of warm food, including traditional items like steamed buns, and stores in Chengdu offer a full variety of onigiri (饭团). Beverages, alcohol, candy, periodicals, and other convenience items are available as well. The majority of these stores are open for 24 hours a day. As of September 2021, 7-Eleven has 2,582 stores in mainland China.
For their launch into space, there is today an unused superpower rocket, Energia, which is the most powerful in the world. In the late 1980s, the Soviet Union built the Mir orbital station. It was built on the construction of Salyut stations and its only role was civilian-grade research tasks. Mir was the only orbital station in operation from 1986 to 1998. Gradually, other modules were added to it, including American modules. However, the station deteriorated rapidly after a fire on board and was deorbited in 2001, burning up in the Earth's atmosphere.
Aronson JK (2008). Meyler's Side Effects of Herbal Medicines. Elsevier. ISBN 978-0-08-093290-3. Braun L, Cohen M (2007). Herbs and Natural Supplements: An Evidence-Based Guide. Elsevier. ISBN 978-0-7295-3796-4.
=== Classes of immunoglobulins (Igs) === The immune system produces several classes of immunoglobulins (Ig), such as IgA, IgD, IgE, IgG, and IgM. Each class helps protect the body from infection in a different way (see below).
Sources: en.wikipedia.org
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.
PDE5 inhibitors act on peripheral vascular tissue to increase blood flow. Bremelanotide acts centrally on melanocortin receptors and is associated with dopaminergic pathways. The two approaches therefore target different parts of the arousal response.
It is a synthetic peptide analog rather than a hormone produced by the body. Alpha-melanocyte-stimulating hormone is the natural peptide it resembles. The two share structural features but are distinct molecules.
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.